Images

Filter by

Figure 1 Pathophysiology of Tissue Congestion
Figure 1: Pathophysiology of Tissue Congestion
Figure 2 Landmark Clinical Trials on Finerenone in Relation to Left Ventricular Ejection Fraction Spectrum
Figure 2: Landmark Clinical Trials on Finerenone in Relation to Left Ventricular Ejection Fraction Spectrum
Table 3 Phase III Clinical Trials of Finerenone on Cardiovascular and Renal Outcomes
Table 3: Phase III Clinical Trials of Finerenone on Cardiovascular and Renal Outcomes
Table 2 Phase II Clinical Trials Evaluating the Safety and Efficacy of Finerenone in Patients with Heart Failure Chronic Kidney Disease and or Type 2 Diabetes
Table 2: Phase II Clinical Trials Evaluating the Safety and Efficacy of Finerenone in Patients with Heart Failure, Chronic Kidney Disease and/or Type 2 Diabetes
Table 1 Characteristics of Mineralocorticoid Receptor Antagonists
Table 1: Characteristics of Mineralocorticoid Receptor Antagonists
Figure 1 Mechanism of Action of Finerenone on the Heart and Kidneys
Figure 1: Mechanism of Action of Finerenone on the Heart and Kidneys
Figure 3 Aldosterone modulating Therapies
Figure 3: Aldosterone-modulating Therapies
Table 3 Cont
Table 3: Cont.
Table 3 Clinical Trials with Potassium Binders
Table 3: Clinical Trials with Potassium Binders
Figure 2 Management of Dyskalaemia
Figure 2: Management of Dyskalaemia
Table 2 Management Strategy for Dyskalaemia
Table 2: Management Strategy for Dyskalaemia
Table 1 Acute Management of Hyperkalaemia
Table 1: Acute Management of Hyperkalaemia